The mechanism and clinical significance of loss of CEACAM1 expression in hepatocellular carcinoma
The mechanism and clinical significance of loss of CEACAM1 expression in hepatocellular carcinoma
批准号:
18591504
负责人:
WAKAI Toshifumi
金额:
$2.34万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
癌胚抗原相关细胞粘附分子1(CEACAM 1),免疫球蛋白超家族的粘附分子,已被表征为推定的肿瘤抑制因子,因为它经常在侵袭性类型的癌细胞中下调。然而,最近的一些研究表明,CEACAM 1在某些类型的肿瘤细胞中积极促进恶性进展或迁移,这表明CEACAM 1的作用在不同类型的癌细胞中可能是不同的。为了研究CEACAM 1在肝细胞癌中表达的功能后果,我们分析了肝癌细胞系HLF、PLC/PRF/5、HepG 2和KYN-2中CEACAM 1的状态。我们发现CEACAM 1仅在HepG 2细胞中表达,其显示出增强的锚定非依赖性生长的独特性质。当用针对CEACAM 1的小干扰RNA处理HepG 2细胞时,单层培养中的生长速率增加。相反,当HepG 2细胞悬浮培养时,CEACAM 1表达的抑制显著降低了生长速率,并且细胞-细胞粘附的速度被抑制。透明质酸酶处理减弱了悬浮培养中HepG 2细胞的生长速率,表明细胞-细胞附着是锚定非依赖性生长的必要条件。我们的数据可能揭示了CEACAM 1在肝癌发生中的双重作用,通过显示CEACAM 1在HepG 2细胞中在锚定依赖性生长条件下作为肿瘤抑制因子,而在锚定非依赖性生长条件下,它通过增强细胞-细胞附着来增强细胞增殖。
英文摘要
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an adhesion molecule of the immunoglobulin superfamily, has been characterized as a putative tumor suppressor because it is frequently down-regulated in aggressive types of cancer cells. Recently, however, several studies have shown that CEACAM1 actively contributes to malignant progression or migration in some types of tumor cells, suggesting that the role of CEACAM1 might be diverse among different types of cancer cells. To investigate the functional consequences of CEACAM 1 expression in hepatocellular carcinoma, we analyzed the status of CEACAM1 in hepatoma cell lines HLF, PLC/PRF/5, HepG2 and KYN-2. We found that CEACAM1 was only expressed in HepG2 cells, which show a unique property for enhanced anchorage-independent growth. When HepG2 cells were treated with small interfering RNA targeted against CEACAM1, the growth rate in monolayer culture was increased. In contrast, when HepG2 cells were cultured in suspension, inhibition of CEACAM1 expression significantly decreased the growth rate, and the speed of cell-cell attachment was repressed. Hyaluronidase treatment attenuated the growth rate of HepG2 cells in suspension culture, indicating that cell-cell attachment is a requisite for anchorage-independent growth. Our data may reveal the dual role of CEACAM1 on hepatocarcinogenesis, by showing that CEACAM1 acts as a tumor suppressor in HepG2 cells in anchorage-dependent growth conditions, while in anchorage-independent growth conditions, it augments cell proliferation by potentiating the cell-cell attachment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-term outcomes after hepatectomy for recurrences after prior local ablation for hepatocellular carcinoma.
肝细胞癌局部消融术后复发的肝切除术后的长期结果。
DOI:
--
发表时间:
2007
期刊:
European Journal of Surgical Oncology
影响因子:
--
作者:
[Sakata J, Shirai Y, Wakai T, et. al.]
通讯作者:
et. al.
DOI:
10.1016/j.lfs.2007.06.002
发表时间:
2007-07-04
期刊:
LIFE SCIENCES
影响因子:
6.1
作者:
[Hokari, Mariko, Matsuda, Yasunobu, Aoyagi, Yutaka]
通讯作者:
Aoyagi, Yutaka
脈管侵襲を伴う肝細胞癌における細胞接着因子の臨床的意義
细胞粘附因子在肝细胞癌伴血管侵犯中的临床意义
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[Pavel Korita, 若井俊文, 白井良夫, 他]
通讯作者:
他
Early DNA damage response in residual carcinoma in situ at ductal stumps and local recurrence in patients undergoing resection for extrahepatic cholangiocarcinoma
-
批准号:24592021
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2012
-
负责人:WAKAI Toshifumi
-
依托单位:
Alteration of p53-binding protein 1 expression as a risk factor for local recurrence in patients undergoing resection for extrahepatic cholangiocarcinoma
-
批准号:21591768
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.58万
-
财政年份:2009
-
负责人:WAKAI Toshifumi
-
依托单位:
Clinical significance of lymph node micrometastasis in ampullary carcinoma
-
批准号:16591301
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:2004
-
负责人:WAKAI Toshifumi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基因IV型猪戊型肝炎病毒ORF3蛋白介导HepG2核黄素代谢通路circRNA的鉴定及调控机理研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:焦寒伟
-
依托单位:
lncRNA CASC9竞争性结合miR-29a靶向IFITM3对肝癌细胞HepG2迁移、侵袭影响的机制研究
-
批准号:2022J011300
-
项目类别:省市级项目
-
资助金额:7.0万元
-
批准年份:2022
-
负责人:陈文
-
依托单位:
姜黄素调控 NLRP3/Caspase-1/IL-1 β通路抑制HepG2 细胞增殖与侵袭的作用机制研究
-
批准号:2021JJ40619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:左清平
-
依托单位:
LncRNA-SNHG7下调靶基因miR-146a-5p调控肝癌HepG2细胞增殖、迁移和侵袭、凋亡
-
批准号:2020JJ8038
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:唐华燕
-
依托单位:
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
-
批准号:22007020
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:周志
-
依托单位:
Cis-trans异构对脂肪酸热氧化行为和HepG2细胞氧化损伤的影响研究
-
批准号:32060579
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:张伟敏
-
依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:周志
-
依托单位:
基于氧化应激进程探索“类天然” 2-氨基吩嗪衍生物靶向 TrxR1 诱导 HepG2 凋亡及其与靶标形成稳定复合物机制研究
-
批准号:81872757
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:陆园园
-
依托单位:
不同保存期单采血小板微粒释放规律及其对HepG2肝癌细胞增殖影响和机制研究
-
批准号:81770194
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2017
-
负责人:汪德清
-
依托单位:
糖基亲水型磁性复合物的构筑及其在HepG2细胞糖蛋白组学分析方法的研究
-
批准号:21505034
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2015
-
负责人:纪永升
-
依托单位: